Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ: HROW ) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ: VTRS ). Viatris To Sell Tyrvaya To Harrow In Up To $100 Million Deal Tyrvaya is a cholinergic agonist indicated for signs and symptoms of dry eye disease and is currently approved in t